FDC Share Price
345.15+3.55 (+1.04%)
-25.61% past 1 Year
FDC Limited make modest beginning in 1936, with marketing of vitamins and a range of prescription formulations. The company is among India’s leading fully integrated pharmaceutical companies. The Company is
Corporate filings & documents
Announcements
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Nandan Mohan Chandavarkar
1 day agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Nandan Mohan Chandavarkar
1 day agoBRSR for FY 2025-26
2 days agoBRSR for FY 2025-26
2 days agoThis is to inform you that the register of members and share transfer books of the Company will remain closed from Thursday September 17 2026 to Wednesday September 23 2026 (both days inclusive) for the 86th AGM of the Company. The cut-off date shall be Wednesday September 16 2026
2 days agoThis is to inform you that the register of members and share transfer books of the Company will remain closed from Thursday September 17 2026 to Wednesday September 23 2026 (both days inclusive) for the 86th AGM of the Company. The cut-off date shall be Wednesday September 16 2026
2 days agoAnnual Report for FY 2025-26
2 days agoAnnual Report for FY 2025-26
2 days agoPlease find enclosed Notice of 86th Annual General meeting for the FY 2025-26
2 days agoPlease find enclosed Notice of 86th Annual General meeting for the FY 2025-26
2 days agoPlease find attached copies of the newspaper advertisement in respect of the 86th AGM of the Company
3 days agoPlease find attached copies of the newspaper advertisement in respect of the 86th AGM of the Company
3 days agoAnnouncement under Regulation 30
1 week agoAnnouncement under Regulation 30
1 week agoThis is to inform you that the companys Subsidiary FDC International Ltd. has received Marketing Authorisation from the MHRA UK for Atropine 1.0% w/v Eye Drops Solution.
3 weeks agoThis is to inform you that the companys Subsidiary FDC International Ltd. has received Marketing Authorisation from the MHRA UK for Atropine 1.0% w/v Eye Drops Solution.
3 weeks agoPress Release Q1 FY 2026-27 Results.
4 weeks agoPress Release Q1 FY 2026-27 Results.
4 weeks agoFinancial Results for the quarter ended June 30 2026
1 month agoFinancial Results for the quarter ended June 30 2026
1 month agoOutcome for the Board Meeting Held on 5th August 2026.
1 month agoOutcome for the Board Meeting Held on 5th August 2026.
1 month agoCertificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended June 30 2026
1 month agoCertificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended June 30 2026
1 month agoFDC Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 inter alia to consider and approve Intimation of Board Meeting to be held on Wednesday August 05 2026. Inter alia to consider and approve the unaudited Standalone & Consolidated Financial Results for the quarter ended June 30 2026.
1 month agoFDC Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 inter alia to consider and approve Intimation of Board Meeting to be held on Wednesday August 05 2026. Inter alia to consider and approve the unaudited Standalone & Consolidated Financial Results for the quarter ended June 30 2026.
1 month agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Sandhya Mohan Chandavarkar Trust (through its Managing Trustee Nandan Mohan Chandavarkar) & PACs
2 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Sandhya Mohan Chandavarkar Trust (through its Managing Trustee Nandan Mohan Chandavarkar) & PACs
2 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Mohan Anand Chandavarkar Trust (through its Managing Trustee Nandan Mohan Chandavarkar) & PACs
2 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Mohan Anand Chandavarkar Trust (through its Managing Trustee Nandan Mohan Chandavarkar) & PACs
2 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Nandan Mohan Chandavarkar & PACs
2 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Nandan Mohan Chandavarkar & PACs
2 months agoTrading Window of the Company shall remain closed for all the Designated persons Connected persons and their relative(s) with effect from July 01 2026 till 48 hours after the declaration of Unaudited Financial results of the company for the quarter ending on June 30 2026.
2 months agoTrading Window of the Company shall remain closed for all the Designated persons Connected persons and their relative(s) with effect from July 01 2026 till 48 hours after the declaration of Unaudited Financial results of the company for the quarter ending on June 30 2026.
2 months agoAnnouncement under Regulation 30 of SEBI (LODR) Regulation 2015
3 months agoPlease find attached the outcome of Postal Ballot
3 months agoPlease find attached the scrutinizer report for Postal Ballot
3 months agoAnnual Secretarial Compliance report of FDC Limited for Financial year ending March 31 2026.
3 months agoAnnual Secretarial Compliance report of FDC Limited for Financial year ending March 31 2026.
3 months agoThis is with regards to our intimation made on May 27 2026 for Press Release wherein there was typographical error in the Subject line of Press Release in the mentioned year which shall be read as " Press release on Q4 - FY 2025-26 and 12 M - FY 2025-26 Results".
3 months agoThis is with regards to our intimation made on May 27 2026 for Press Release wherein there was typographical error in the Subject line of Press Release in the mentioned year which shall be read as " Press release on Q4 - FY 2025-26 and 12 M - FY 2025-26 Results".
3 months agoPress release on Q4 FY 2026-27 and 12 months FY 2026-27 results
3 months agoPress release on Q4 FY 2026-27 and 12 months FY 2026-27 results
3 months agoApproved Standalone and consolidated financial results for the financial year ending March 31 2026
3 months agoApproved Standalone and consolidated financial results for the financial year ending March 31 2026
3 months agoBoard meeting outcome for approval of the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended on March 31 2026.
3 months agoBoard meeting outcome for approval of the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended on March 31 2026.
3 months agoFDC Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2026 inter alia to consider and approve Intimation of Board Meeting to be held on Wednesday May 27 2026 inter-alia to consider and approve the Audited Standalone & Consolidated Financial Results of the Company for Quarter and Year ended March 31 2026.
3 months agoFDC Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2026 inter alia to consider and approve Intimation of Board Meeting to be held on Wednesday May 27 2026 inter-alia to consider and approve the Audited Standalone & Consolidated Financial Results of the Company for Quarter and Year ended March 31 2026.
3 months agoAnnouncement under Regulation 30 - ANDA approval
3 months agoAnnual reports
Concalls & investor presentations
Nov 2023
ConcallPresentation
Nov 2023
ConcallPresentation
Feb 2023
ConcallPresentation
Nov 2022
ConcallPresentation
Nov 2022
ConcallPresentation
Aug 2022
ConcallPresentation
Aug 2022
ConcallPresentation
May 2022
ConcallPresentation
May 2022
ConcallPresentation
Feb 2022
ConcallPresentation
Corporate Actions
Date
Type
Details
2026-02-11
Dividend
5.0
2024-11-22
Dividend
5.0
2020-03-19
Dividend
0.8
2017-08-08
Dividend
2.25
2016-03-17
Dividend
2.25
2015-09-23
Dividend
2.25
2014-07-28
Dividend
2.25
2013-08-20
Dividend
2.25
2012-08-06
Dividend
2.0
2011-09-13
Dividend
2.0
2010-08-10
Dividend
1.75
Company details
Registered office
B-8 Midc Industrial Area Waluj Dist Chhatrapati Sambhajinagar - (Aurangabad) Maharashtra PIN: 431136 Tel No: 0240- 2554407 / 2554967 / 2554299 Fax No: 0240- 2554299 Email: [email protected] Internet: www.fdcindia.com
Registrars
C 101, 247 Park, L B S Marg, Vikhroli (West), Mumbai 400 083.Tel: 2851 5606/ 2851 5644 Fax: 2851 2885E-mail: [email protected] C 101, 247 Park L B S Marg Vikhroli (West) PIN: Tel No: 2851 5606/ 2851 5644 Fax No: 2851 2885 Email: [email protected] Internet: https://in.mpms.mufg.com/
Management
Varsharani Katre, Company Secretary & Compliance Officer
Mohan A Chandavarkar, Managing Director
Nandan M Chandavarkar, Joint Managing Director
Ashok A Chandavarkar, Whole Time Director
Ameya A Chandavarkar, Whole Time Director - International Business & CEO
Nomita R Chandavarkar, Non Independent & Non Executive Director
Mahesh Bijlani, Non Executive Independent Director
Vijay Maniar, Non Executive Independent Director
Vijay Nautamlal Bhatt, Non Executive Independent Director
Charuta Nityanath Mandke, Non Executive Independent Director
Kishore Mukund Saletore, Independent Director
Details
BSE 531599
NSE FDC
ISIN INE258B01022